Viiv Healthcare Co
General
Total Cases35
Active Cases5
Patents166
Ratings
Experience
Grade
Trend
DCT
L4
A
PTAB
L5
E
CAFC
L3
E
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 10/24/24 | Summons Issued as to Hetero Labs Limited on 10/23/2024; Hetero Labs Limited Unit-III on 10/23/2024; Hetero USA Inc. on 10/23/2024. (Attachments: # [1] Summons Issued, # [2] Summons Issued)(oam) (Entered: 10/24/2024) | |
| 10/24/24 | Summons Issued as to Hetero Labs Limited on 10/23/2024; Hetero Labs Limited Unit-III on 10/23/2024; Hetero USA Inc. on 10/23/2024. (Attachments: # [1] Summons Issued, # [2] Summons Issued)(oam) (Entered: 10/24/2024) | |
| 10/24/24 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Pfizer Inc., Corporate Parent GlaxoSmithKline plc., Corporate Parent Shionogi Limited, Other Affiliate Shionogi & Co., Ltd. for ViiV Healthcare Company, ViiV Healthcare UK (No. 3) Limited filed by ViiV Healthcare Company, ViiV Healthcare UK (No. 3) Limited. (oam) (Entered: 10/24/2024) | |
| 10/24/24 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Pfizer Inc., Corporate Parent GlaxoSmithKline plc., Corporate Parent Shionogi Limited, Other Affiliate Shionogi & Co., Ltd. for ViiV Healthcare Company, ViiV Healthcare UK (No. 3) Limited filed by ViiV Healthcare Company, ViiV Healthcare UK (No. 3) Limited. (oam) (Entered: 10/24/2024) | |
| 10/24/24 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Shionogi & Co., Ltd. (oam) Modified on 10/24/2024 (oam). (Entered: 10/24/2024) | |
| 10/24/24 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Shionogi & Co., Ltd. (oam) Modified on 10/24/2024 (oam). (Entered: 10/24/2024) | |
| 10/24/24 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,242,986. (oam) (Entered: 10/24/2024) | |
| 10/24/24 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,242,986. (oam) (Entered: 10/24/2024) | |
| 10/24/24 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/20/2024. Date of Expiration of Patent: 12/08/2029.Thirty Month Stay Deadline: 3/20/2027. (oam) (Entered: 10/24/2024) | |
| 10/24/24 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 09/20/2024. Date of Expiration of Patent: 12/08/2029.Thirty Month Stay Deadline: 3/20/2027. (oam) (Entered: 10/24/2024) |